- Home
- LUD vs MIST Comparison
LUD vs MIST Comparison
Compare LUD & MIST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LUD
- MIST
- Stock Information
- Founded
- LUD 2004
- MIST 2003
- Country
- LUD Hong Kong
- MIST Canada
- Employees
- LUD N/A
- MIST N/A
- Industry
- LUD
- MIST Biotechnology: Pharmaceutical Preparations
- Sector
- LUD
- MIST Health Care
- Exchange
- LUD NYSE
- MIST Nasdaq
- Market Cap
- LUD 96.7M
- MIST 89.8M
- IPO Year
- LUD 2025
- MIST N/A
- Fundamental
- Price
- LUD $6.09
- MIST $1.79
- Analyst Decision
- LUD
- MIST Strong Buy
- Analyst Count
- LUD 0
- MIST 2
- Target Price
- LUD N/A
- MIST $7.50
- AVG Volume (30 Days)
- LUD 35.4K
- MIST 665.5K
- Earning Date
- LUD 01-01-0001
- MIST 08-07-2025
- Dividend Yield
- LUD N/A
- MIST N/A
- EPS Growth
- LUD N/A
- MIST N/A
- EPS
- LUD N/A
- MIST N/A
- Revenue
- LUD $44,863,430.00
- MIST N/A
- Revenue This Year
- LUD N/A
- MIST N/A
- Revenue Next Year
- LUD N/A
- MIST N/A
- P/E Ratio
- LUD N/A
- MIST N/A
- Revenue Growth
- LUD N/A
- MIST N/A
- 52 Week Low
- LUD $3.40
- MIST $0.63
- 52 Week High
- LUD $8.00
- MIST $2.75
- Technical
- Relative Strength Index (RSI)
- LUD N/A
- MIST 65.16
- Support Level
- LUD N/A
- MIST $1.65
- Resistance Level
- LUD N/A
- MIST $1.80
- Average True Range (ATR)
- LUD 0.00
- MIST 0.09
- MACD
- LUD 0.00
- MIST -0.01
- Stochastic Oscillator
- LUD 0.00
- MIST 86.03
About LUD LUDA TECHNOLOGY GROUP LIMITED
Luda Technology Group Ltd is a company that is principally engaged in the manufacture and sale of stainless steel and carbon steel flanges and fittings products and trading of steel pipes, valves, and other steel tubing products.
About MIST Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular medicines. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to treat episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).